British patients will lose the chance of treatment with Roche’s latest and most expensive cancer medicine after the Swiss pharmaceuticals group refused to co-operate with the government’s medicines advisory body.

The National Institute for Clinical Health and Excellence, or Nice, has advised against the National Health Service using Avastin for first-line lung and breast cancer after Roche declined to answer requests for data on the drug’s clinical and cost-effectiveness.